top of page

This is a list of publications authored or co-authored by RTMP members fitting within the themes of RTMP. 

Systematic review and network meta-analysis of stroke prevention treatments in patients with atrial fibrillation. Tawfik A, Bielecki JM, Krahn M, Dorian P, Hoch JS, Boon H, Husereau D, Pechlivanoglou P. Clin Pharmacol. 2016; 8:93-107.

The PIP-STOPP study: Assessing Potentially Inappropriate Prescribing in (PIP) and predicting patient outcomes using a subset of the STOPP criteria in Ontario’s older population: a population-based cohort study using large health administrative databases. Bjerre LM, Ramsay T, Cahir C, Ryan C, Halil R, Farrell B, Thavorn K, Catley C, Hawken S, Gillespie U, Manuel DG.  BMJ Open. 2015;5:e010146.


Potentially Inappropriate Prescribing (PIP) in Long-Term Care (LTC) patients: validation of the 2014 STOPP-START and 2012 Beers criteria in a LTC population -- a protocol for a cross-sectional comparison of clinical and health administrative data. Bjerre LM, Halil R, Catley C, Farrell B, Hogel M, Black CD, Williams M, Ryan C, Manuel DG.  BMJ Open. 2015;5:e009715.


Trends in antiparkinson drug use in the United States, 2001-2012. Crispo J, Fortin Y, Emons M, Bjerre LM, Kohen D, Perez Lloret S, Mattison D, Willis A, Krewski D. European Journal of Clinical Pharmacology. In Press, June 2015.


Antibiotics for community-acquired pneumonia in adult outpatients. (Cochrane Review Update). Pakhale S, Mulpuru S, Verheij TJ, Kochen MM, Rohde GG, Bjerre LM.  Cochrane Database Syst Rev. 2014 Oct 9;10:CD002109.


Comparative effectiveness of monotherapies and combination therapies for patients with hypertension: protocol for a systematic review with network meta-analysis. Hutton B, Tetzlaff J, Yazdi F, Thielman J, Kanji S, Fergusson D, Bjerre LM, Mills E, Thorlund K, Tricca A, Straus S, Moher D, Lennen F HH. Systematic Reviews. 2013; 2:44.

Do statins cause cancer? A meta-analysis of large randomized clinical trials. Bjerre LM, LeLorier J. American Journal of Medicine. 2001;110:716-23.

Influence of female gender on hepatitis C virus infection progression and treatment outcomes. Corsi DJ, Karges W, Thavorn K, Crawley AM, Cooper C. European Journal of Gastroenterology and Hepatology. 2016; In Press.

Identifying strategies to improve diabetes care in Alberta, Canada, using the knowledge-to-action cycle. Manns B, Braun T, Edwards A, Grimshaw J, Hemmelgarn B, Husereau D, et al. CMAJ Open. 2013;1(4):E142–50.


Efficacy of statins for primary prevention in people at low cardiovascular risk: a meta-analysis. Tonelli M, Lloyd A, Clement F, Conly J, Husereau D, Hemmelgarn B, et al. CMAJ. 2011;183(16):E1189–202.


Potential effects of rational prescribing on national health care spending: More than half a billion dollars in annual savings. Littman, J. and Halil, R. Canadian Family Physician. March 2016, 62 (3) 235-244. 

Merger Mania: Mergers and acquisitions in the generic drug sector from 1995 to 2016. Gagnon, M-A (principal author), Volesky, K. Globalization and Health. 2017 Aug; 13 (62): 1-7.​

The role and impact of cost-sharing mechanisms for prescription drug coverage. Gagnon, M-A. Canadian Medical Association Journal 2017; 189 (19): E680-E681.


Reimbursement-based economics – what is it and how can we use it to inform drug policy reform? Coyle D, Lee KM, Mamdani M, Sabarre K-A, Tingley K. Headache. 2015 Jul;55 Suppl 4:236-47.


What guidance are economists given on how to present economic evaluations for policymakers? Sullivan SM, Wells G, Coyle D. A systematic review. Value Health. 2015;18(6):915-24.


Cost effectiveness of continued warfarin versus heparin bridging therapy during pacemaker and defibrillator surgery. Coyle D, Coyle K, Essebag V, Birnie DH, Ahmad K, Toal S et al. Journal of American College of Cardiology 2015 Mar 10;65(9):957-9.


The need for transparency and efficiency in reimbursement decisions relating to drugs for rare diseases. Coyle D, Cheung MC Evans GA. Medical Decision Making 2015 Feb;35(2):145-7.


Economic evaluation of a hospital-initiated intervention for smokers with chronic disease, in Ontario, Canada. Mullen KA, Coyle D, Manuel D, Nguyen HV, Pham B, Pipe AL, Reid RD. Tobbaco Control. 2015;24(5):489-96.

EQUIPT: protocol of a comparative effectiveness research study evaluating cross-context transferability of economic evidence on tobacco control. Pokhrel S, Evers S, Leidl R, Trapero-Bertran M, Kalo Z, Vries Hd, Crossfield A, Andrews F, Rutter A, Coyle K, Lester-George A, West R, Owen L, Jones T, Vogl M, Radu-Loghin C, Voko Z, Huic M, Coyle D. BMJ Open. 2014 Nov 24;4(11):e006945


Funding drugs for rare diseases: the cost effectiveness of eculizumab in paroxysmal nocturnal hemoglobinuria. Coyle D, Cheung MC Evans GA. Medical Decision Making 2014;34(8):1016-29.


Application of a policy framework for the public funding of drugs for rare diseases. Winquist E, Coyle D, Clarke JTR, Evans GA, Seager C, Chan W, Martin J. J Gen Intern Med 2014 Aug;29 Suppl 3:S774-9.


Cost effectiveness of a survivorship care plan for breast cancer survivors. Coyle D, Grunfeld E, Coyle K, Pond G, Julian J, Levine M. Journal of Oncology Practice 2014 10(2):e86-92.

Cost-effectiveness of new oral anticoagulants compared to warfarin in preventing stroke and other cardiovascular events in patients with atrial fibrillation.  Coyle D, Coyle K, Cameron C, Lee K, Kelly S, Steiner S et al. Value in Health 2013;16(4):498-506


Economic analysis of a randomized phase III trial of gemcitabine plus vinorelbine compared with cisplatin plus vinorelbine or cisplatin plus gemcitabine for advanced non-small-cell lung cancer (Italian GEMVIN3/NCIC CTG BR14 trial).  Reaume MN, Leighl NB, Mittmann N, Coyle D, Hirsh V, Seymour L et al. Lung Cancer. 2013 82(1):115-20.

An evaluation framework for funding drugs for rare disease. Winquist E,  Bell CM, Clarke JTR, Evans G, Martin J, Sabharwal M, Gadhok A, Stevenson H, Coyle D. Value in Health 2012:15; 982–986


Cost effectiveness of exercise programs in Type 2 diabetes. Coyle D, Coyle K, Kenny GP, Boulé NG, Wells GA, Fortier M, Reid RD, Phillips P, Sigal RJ. Int J Technol Assess Health Care. 2012 Jul;28(3):228-34.


Cost effectiveness of infant vaccination for rotavirus in Canada. Coyle D, Coyle K, Bettinger JS, Halperin SA, Vaudry W, Scheifele DW, Le Saux N. CJIDDM. 2012:23:71-77.


(Correcting) misdiagnoses of asthma: a cost effectiveness analysis. Pakhale S, Sumner A, Coyle D, Vandemheem K, Aaron S. BMC Pulm Med. 2011;11(1):27.

How do we value a cure? Husereau D. Expert Rev Pharmacoecon Outcomes Res. 2015;15(4):551–5.


Evolution of drug reimbursement in Canada: the pan-canadian pharmaceutical alliance for new drugs. Husereau D, Dempster W, Blanchard A, Chambers J. Value Health. 2014;17(8):888–94.


How do Economic Evaluations Inform Health Policy Decisions for Treatment and Prevention in Canada and the United States? Husereau D, Culyer AJ, Neumann P, Jacobs P. Appl Health Econ Health Policy. 2014:13(3):273-9.


Incorporating economic evaluation into immunization decision making in Canada: a workshop. Langley JM, Krahn M, Husereau D, Spika J, Fisman DN, Chit A, et al. Expert Rev Vaccines. 2014;13(11):1291–6.


Cost-effectiveness of the use of low- and high-potency statins in people at low cardiovascular risk. Conly J, Clement F, Tonelli M, Hemmelgarn B, Klarenbach S, Lloyd A, Husereau D, et al CMAJ. 2011;183(16):E1180–8.


Value-Based Pricing of Pharmaceuticals in Canada: Opportunities to Expand the Role of Health Technology Asessment? Husereau D, Cameron CG. Ottawa: Canadian Foundation for Healthcare Improvement; 2011.


A cost-effectiveness analysis of a community pharmacist based smoking cessation program. Thavorn K, Chaiyakunapruk N. Tobacco Control. 2008; 17:177-182.


Direct costs of adult chronic rhinosinusitis using four methods of estimation: results of the US Medical Expenditure Panel Survey. Caulley L, Thavorn K, Rudmik L, Cameron C, Kilty SJ. Journal of Allergy and Clinical Immunology. 2015; 136(6):1517-22.

Health Systems

What Canadians need to know about their medication: Report of the 2017 RTMP national stakeholder roundtable. Bjerre et el. 2018; January. 

A comparative study of the format, content and timing of medication safety letters issued in Canada, the US and the UK. Bjerre, LM et al. BMJ Open (accepted with revision). 2018.


A Better Prescription: Advice for a National Strategy on Pharmaceutical Policy in Canada. Morgan SG, Gagnon MA, Mintzes B, Lexchin J. Health Policy. 2016;12(1):18-36.

New Drug Pricing; Does it make any sense? Gagnon M-A.  Prescrire International 24 (162), 2015: 192-195. English translation of  « Pourquoi les médicaments sont-ils si chers? Les dérives d’un modèle d’affaires. » Prescrire  35 (380), 2015: 457-461.


The Future of Drug Coverage in Canada. Morgan SG, Martin D, Gagnon M-A, Barbara Mintzes, Daw JR, Lexchin J. Pharmacare 2020; Published by the Pharmaceutical Policy Research Collaboration, University of British Columbia. July 15 2015.


Reforming Private Drug Coverage in Canada; Inefficient Drug Benefit Design and the Barriers to Change in Unionized Settings. O’Brady S, Gagnon M-A, Cassels A. Health Policy. 2015;119(2):224-31.


A Roadmap to Rational Pharmacare Policy in Canada. Gagnon M-A. Ottawa: Canadian Federation of Nurses Unions. August 2014.

Corruption of Pharmaceutical Markets: Addressing the Misalignment of Financial Incentives and Public Health. Gagnon M-A. Journal of Law, Medicine and Ethics. 2013;41(3):571-580.


Adaptive approaches to licensing, health techonology assessment and introduction to drugs and devices. Husereau D. 2014;30(3):241–9.


How do Economic Evaluations Inform Health Policy Decisions for Treatment and Prevention in Canada and the United States? Husereau D, Culyer AJ, Neumann P, Jacobs P. Appl Health Econ Health Policy. 2014;13(3):273-9.



Resource Allocation


bottom of page